PDCD1 and lung carcinoma: Meng et al. demonstrated that inhibition of this interaction by stragaloside IV or astragaloside IV causes a decrease in the extracellular secretion of IDO1 and increases the antitumor effect of PD-1 inhibitors in lung cancer cells both in-vivo and in-vitro (Table 1) [116].